Table 3.
Patient number | Dose D 0 | Dose 6 months | Dose adjustment |
---|---|---|---|
1b | 4 mg | 3 mg | Reduction |
3b | 0.5 mg | 1 mg | Rise |
4b | 3 mg | 3 mg | None |
5b | 3 mg | 2.5 mg | Reduction |
7b | 2 mg | 1 mg | Reduction |
8b | 3 mg | 3 mg | None |
9b | 2 mg | 2 mg | None |
11b | 1 mg/1.5 mg | 1 mg/1.5 mg | None |
12b | 1.5 mg | 1 mg | Reduction |
13b | 2.5 mg | 2.5 mg | None |
14b | 3 mg | 3 mg | None |
16b | 10 mg | 6 mg | Reduction |
17b | 2 mg | 2 mg | None |
18b | 2 mg | 2 mg | None |
19b | 6 mg | 6 mg | None |
20b | 1.5 mg | 1.5 mg | None |
21b | 2 mg | 2 mg | None |
23b | 3 mg | 3 mg | None |
24b | 2 mg | 2 mg | None |
25b 2 mg | 2 mg | None |
Notes: Six patients in the original group (Prograf ® or Advagraf ® [TAC] and CellCept® [MMF]) needed dose adjustments. The majority of dose adjustments were dose reductions (D 0: day 0). Dose adjustments are written in bold.
Abbreviations: TAC, tacrolimus; MMF, mycophenolate mofetil.